Literature DB >> 9543205

Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression.

S N Seidman1, J G Rabkin.   

Abstract

BACKGROUND: Testosterone replacement therapy is an effective treatment of some depressive symptoms in hypogonadal men, and may be an effective augmentation treatment for SSRI-refractory major depression in such men.
METHODS: We treated five depressed men who had low testosterone levels and had not responded to an adequate SSRI trial with 400 mg testosterone replacement biweekly for 8 weeks. Four patients underwent single-blind placebo discontinuation. Patients were assessed at baseline and biweekly thereafter using the Hamilton Depression Rating Scale (HAM-D) and the Endicott Quality of Life Enjoyment and Satisfaction Scale (Q-LES-Q).
RESULTS: Patients' mean age was 40 years, and mean testosterone level 277 ng/dl. All had a rapid and dramatic recovery from major depression following testosterone augmentation: mean 21-item HAM-D decreased from 19.2 to 7.2 by week 2, and to 4.0 by week 8; mean Q-LES-Q increased from 45% to 68%. Three of four subjects who underwent discontinuation of testosterone under single-blind placebo treatment began to relapse.
CONCLUSION: Testosterone replacement therapy may be an effective treatment of depressive symptoms in some men, and warrants further research.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9543205     DOI: 10.1016/s0165-0327(97)00168-7

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  23 in total

Review 1.  Common conditions of the aging male: erectile dysfunction, benign prostatic hyperplasia, cardiovascular disease and depression.

Authors:  L Zakaria; A G Anastasiadis; R Shabsigh
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  A potential relationship between diffuse musculoskeletal pain and hypogonadism.

Authors:  Jaclyn K Anderson; Rebecca Tuetken; Valerie Hoffman
Journal:  BMJ Case Rep       Date:  2010-01-13

3.  Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients.

Authors:  Michael Ritsner; Rena Kurs; Anatoly Gibel; Yael Ratner; Jean Endicott
Journal:  Qual Life Res       Date:  2005-09       Impact factor: 4.147

Review 4.  Hormone treatment of depression.

Authors:  Russell T Joffe
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

5.  The Anxiolytic and Antidepressant-like Effects of Testosterone and Estrogen in Gonadectomized Male Rats.

Authors:  Nicole Carrier; Samantha K Saland; Florian Duclot; Huan He; Roger Mercer; Mohamed Kabbaj
Journal:  Biol Psychiatry       Date:  2015-01-14       Impact factor: 13.382

6.  Quality of sleep in patients receiving androgen deprivation therapy for prostate cancer.

Authors:  Asli Koskderelioglu; Muhtesem Gedizlioglu; Yasin Ceylan; Bulent Gunlusoy; Nilden Kahyaoglu
Journal:  Neurol Sci       Date:  2017-05-08       Impact factor: 3.307

7.  Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  Arch Intern Med       Date:  2006-02-27

Review 8.  Depression in aging men: the role of testosterone.

Authors:  Ryan M Carnahan; Paul J Perry
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 9.  Illicit anabolic-androgenic steroid use.

Authors:  Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Horm Behav       Date:  2009-09-18       Impact factor: 3.587

10.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.